These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 32854135)
1. Telemedicine HCV treatment in department of corrections results in high SVR in era of direct-acting antivirals. Syed TA; Cherian R; Lewis S; Sterling RK J Viral Hepat; 2021 Jan; 28(1):209-212. PubMed ID: 32854135 [TBL] [Abstract][Full Text] [Related]
2. A decade of hepatitis C at the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa, in the pre-direct-acting antivirals era. Nordien R; Sonderup MW; Spearman CW S Afr Med J; 2020 Jan; 110(2):106-111. PubMed ID: 32657679 [TBL] [Abstract][Full Text] [Related]
3. Treatment of HCV in the Department of Corrections in the Era of Oral Medications. Sterling RK; Cherian R; Lewis S; Genther K; Driscoll C; Martin K; Goode MB; Matherly S; Siddiqui MS; Luketic VA; Stravitz RT; Puri P; Lee H; Smith P; Patel V; Sanyal AJ J Correct Health Care; 2018 Apr; 24(2):127-136. PubMed ID: 29566611 [TBL] [Abstract][Full Text] [Related]
4. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland. Bachofner J; Valli PV; Bergamin I; Kröger A; Künzler P; Baserga A; Braun DL; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens J; The Swiss Hepatitis C Cohort Study Swiss Med Wkly; 2018; 148():w14560. PubMed ID: 29376557 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910 [TBL] [Abstract][Full Text] [Related]
6. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa. Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680 [TBL] [Abstract][Full Text] [Related]
7. The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons. Richter V; Goldstein L; Cohen DL; Bermont A; Zelnik Yovel D; Madar M; Rabinovitch R; Shirin H; Broide E Sci Prog; 2022; 105(2):368504221105173. PubMed ID: 35722762 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132 [TBL] [Abstract][Full Text] [Related]
9. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals. Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695 [TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283 [TBL] [Abstract][Full Text] [Related]
11. Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients. Cooper CL; Hatashita H; Corsi DJ; Parmar P; Corrin R; Garber G Ann Hepatol; 2017 November-December,; 16(6):874-880. PubMed ID: 29055923 [TBL] [Abstract][Full Text] [Related]
12. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection. Martin MT; Deming P Pharmacotherapy; 2017 Jun; 37(6):735-747. PubMed ID: 28374965 [TBL] [Abstract][Full Text] [Related]
13. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients. Su F; Beste LA; Green PK; Berry K; Ioannou GN Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):686-693. PubMed ID: 28195877 [TBL] [Abstract][Full Text] [Related]
15. Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil. Lobato CMO; Codes L; Silva GF; Souza AFM; Coelho HSM; Pedroso MLA; Parise ER; Lima LMSTB; Borba LA; Evangelista AS; Rezende REF; Cheinquer H; Kuniyoshi ASO; Aires RS; Quintela EHD; Mendes LSC; Nascimento FCV; Medeiros Filho JEM; Ferraz MLCG; Abdala E; Bittencourt PL; ; Ann Hepatol; 2019; 18(6):849-854. PubMed ID: 31537509 [TBL] [Abstract][Full Text] [Related]
16. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience. Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900 [TBL] [Abstract][Full Text] [Related]
17. Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment. Daniel KE; Saeian K; Rizvi S J Viral Hepat; 2020 Feb; 27(2):195-204. PubMed ID: 31602715 [TBL] [Abstract][Full Text] [Related]
18. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV). Walker DR; Pedrosa MC; Manthena SR; Patel N; Marx SE Adv Ther; 2015 Nov; 32(11):1117-27. PubMed ID: 26538232 [TBL] [Abstract][Full Text] [Related]
19. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study. Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354 [TBL] [Abstract][Full Text] [Related]
20. Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review. Mantry PS; Pathak L Expert Rev Anti Infect Ther; 2016; 14(2):157-65. PubMed ID: 26567871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]